Identification of genetic changes associated with drug resistance by reverse in situ hybridization

British Journal of Cancer

Volumn 75, Issue 2, 1997, Pages 275-282

  Hoare, S F ^a   Freeman, C A ^a   Coutts, J C ^a   Varley, J M ^b   James, L ^b   Keith, W N ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Chromosome painting; Drug resistance; Fluorescence in situ hybridization; Gene amplification; Gene mapping; Molecular cytogenetics; Reverse in situ hybridization

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; CELL DNA; DOXORUBICIN;

ARTICLE; CELL LINE; CHROMOSOME 1Q; CHROMOSOME PAINTING; DRUG RESISTANCE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; PRIORITY JOURNAL;

EID: 0031015631     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.45     Document Type: Article

References (39)

1. Albertsen H, Plaetke R, Ballard L, Fujimoto E, Connolly J, Lawrence E, Rodriguez P, Robertson M, Bradley P, Milner B, Fuhrman D, Marks A, Sargent R, Cartwright P, Matsunami N and White R (1994) Genetic mapping of the BRCA1 region on chromosome 17q21. Am J Hum Genet 54: 516-525
2. Booser DJ and Hortobagyi GN (1994) Anthracycline antibiotics in cancer therapy: focus on drug resistance. Drugs 47: 223-258
3. Bradley G, Juranke PF and Ling V (1988) Mechanism of multidrug resistance. Biochim Biophys Acta 948: 87-128
4. Bray Ward P, Menninger J, Lieman J, Desai T, Mokady N, Banks A and Ward DC (1996) Integration of the cytogenetic, genetic, and physical maps of the human genome by FISH mapping of CEPH YAC clones. Genomics 32: 1-14
5. Chen AY and Liu LF (1994) DNA topoisomerases: essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol 34: 191-218
6. Coutts J, Plumb JA, Brown R and Keith WN (1993) Expression of topoisomerase II alpha and beta in an adenocarcinoma cell line carrying amplified topoisomerase II alpha and retinoic acid receptor alpha genes. Br J Cancer 68: 793-800
7. Eijdems EWHM, De Haas M, CocoMartin JM, Ottenheim CPE, Zaman GJR, Dauwerse HG, Breuning MH. Twentyman PR, Borst P and Baas F (1995) Mechanisms of MRP over-expression in four human lung-cancer cell lines and analysis of the MRP amplicon. Int J Cancer 60: 676-684
8. FroelichAmmon SJ and Osheroff N (1995) Topoisomerase poisons: harnessing the dark side of enzyme mechanism. J Biol Chem 270: 21429-21432
9. Gudkov AV, Kazarov AR, Thimmapaya R, Axenovich SA, Mazo IA and Roninson IB (1994) Cloning mammalian genes by expression selection of genetic suppressor elements: association of kinesin with drug resistance and cell immortalization. Proc Natl Acad Sci USA 91: 3744-3748
10. Harrison DJ (1995) Molecular mechanisms of drug resistance in tumours. J Pathol 175: 7-12
11. Houldsworth J and Chaganti RSK (1994) Comparative genomic hybridization: an overview. Am J Pathol 145: 1253-1260
12. Isola J, DeVries S, Chu L, Ghazvini S and Waldman F (1994) Analysis of changes in DNA sequence copy number by comparative genomic hybridization in archival paraffin-embedded tumor samples. Am J Pathol 145: 1301-1308
13. Jones KA, Black DM, Brown MA, Griffiths BL, Nicolai HM, Chambers JA, Bonjardim M, Xu CF, Boyd M, McFarlane R, Korn B, Poustka A, North MA, Schalkwyk L, Lehrach H and Solomon E (1994) The detailed characterisation of a 400 kb cosmid walk in the BRCA1 region: identification and localisation of 10 genes including a dual specificity phosphatase. Hum Mol Genet 3: 1927-1934
14. Joos S, Scherthan H, Speicher MR, Schlegel J, Cremer T and Lichter P (1993) Detection of amplified DNA sequences by reverse chromosome painting using genomic tumor DNA as probe. Hum Genet 90: 584-589
15. Kallioniemi A, Kallioniemi OP, Piper J, Tanner M, Stokke T, Chen L, Smith HS, Pinkel D, Gray JW and Waldman FM (1994) Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridization. Proc Natl Acad Sci USA 91: 2156-2160
16. Kallioniemi A, Kallioniemi O, Sudar D, Rutovitz D, Gray JW, Waldman F and Pinkel D (1992) Comparative genomic hybridization for molecular cytogenetic analysis of solid tumours. Science 258: 818-821
17. Kallioniemi O, Kallioniemi A, Sudar D, Rutovitz D, Gray JW, Waldman F and Pinkel D (1993) Comparative genomic hybridisation: a rapid new method for detecting and mapping DNA amplification in tumours. Semin Cancer Biol 4: 41-16
18. Kastan MB, Canman CK and Leonard CJ (1995) P53, cell cycle control and apoptosis: implications for cancer. Cancer Metast Rev 14: 3-15
19. Keith WN, Tan KB, Brown R (1992), Amplification of the topoisomerase II alpha gene in a non-small cell lung cancer cell line and characterisation of polymorphisms at the human topoisomerase II alpha and beta loci in normal tissue. Genes Chrom Cancer 4: 169-175
20. Keith WN, Douglas F, Wishart GC, McCallum HM, George WD, Kaye and Brown R (1993) Co-amplification of erbB2, topoisomerase II alpha and retinoic acid receptor alpha genes in breast cancer in allelic loss at topoisomerase 1 on chromosome 20. Eur J Cancer 29: 1469-1475
21. Lehrach H (1990) Genome Analyses Volume 1. Genetic and Physical Mapping, Davies KE and Tilghman SM (eds) pp. 39-81. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY.
22. Lichter P, Tang CC, Call K, Hermanson G, Evans GA, Housman D and Ward DC (1990) High-resolution mapping of human chromosome 11 by in situ hybridization with cosmid clones. Science 247: 64-69
23. Lichter P, Bentz M and Joos S (1995) Detection of chromosomal aberrations by means of molecular cytogenetics: painting of chromosomes and chromosomal subregions and comparative genomic hybridization. Methods Enzymol 254: 334-359
24. McLeod HL and Keith WN (1996) Variation in topoisomerase I gene copy number as a mechanism for intrinsic drug sensitivity. Br J Cancer 74: 508-512
25. Mitelman F (1995). ISCN 1995: An International System for Human Cytogenetic Nomenclature. S Karger: Basle, Switzerland.
26. Murphy DS, McHardy P, Coutts J, Mallon EA, George WD, Kaye SB, Brown R and Keith WN (1995) Interphase cytogenetic analysis of erbB2 and topoIIalpha co-amplification in invasive breast cancer and polysomy of chromosome 17 in ductal carcinoma in situ. Int J Cancer 64: 18-26
27. Murphy DS, Hoare SF, Going JJ, Mallon EEA, George WD, Kaye SB, Brown R, Black DM and Keith WN (1995b) Characterization of extensive genetic alterations in ductal carcinoma in situ by fluorescence in situ hybridization and molecular analysis. J Natl Cancer Inst 87: 1694-1704
28. Neuhausen SL, Swensen J, Miki Y, Liu Q, Tavtigian S, Shattuck Eidens D, Kamb A, Hobbs MR, Gingrich J, Shizuya H, Kim UJ, Cochran C, Futreal PA, Wiseman RW, Lynch HT, Tonin P, Narod S, Cannon Albright L, Skolnick MH and Goldgar DE (1994) A PI-based physical map of the region from D17S776 to D17S78 containing the breast cancer susceptibility gene BRCA1. Hum Mol Genet 3: 1919-1926
29. Pommier Y, Leteurtre F, Fesen MR, Fujimori A, Bertrand R, Solary E, Kohlhagen G and Kohn KW (1994) Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest 12: 530-542
30. Ried T, Just KE, HoltgreveGrez H, Du Manoir S, Speicher MR, Schrock E, Latham C, Belgen H, Zetterberg A, Cremer T and Auer G (1995) Comparative genomic hybridization of formalin-fixed, paraffin-embedded breast tumors reveals different patterns of chromosomal gains and losses in fibroadenomas and diploid and aneuploid carcinomas. Cancer Res 55: 5415-5423
31. Roninson IB, Gudkov AV, Holzmayer TA, Kirschling DJ, Kazarov AR, Zelnick CR, Mazo IA, Axenovich S and Thimmapaya R (1995) Genetic suppressor elements; new tools for molecular oncology - Thirteenth Cornelius P Rhoads Memorial Award Lecture. Cancer Res 55: 4023-4028
32. Sinha BK (1995) Topoisomerase inhibitors. A review of their therapeutic potential in cancer. Drugs 49: 11-19
33. Speicher MR, Du Manoir S, Schrock E, HoltgreveGrez H, Schoell B, Lengauer C, Cremer T and Ried T (1993) Molecular cytogenetic analysis of formalin-fixed, paraffin-embedded solid tumors by comparative genomic hybridization after universal DNA-amplification. Hum Mol Genet 2: 1907-1914
34. Stark GR, (1993) Regulation and mechanisms of mammalian gene amplification. Adv Cancer Res 61: 87-113
35. Su TL, Chou TC and Watanabe KA (1992) DNA topoisomerase targeted anticancer agents: new trends and developments. Curr Opin Therap Patents 2: 1121-1139
36. Takano H, Kohno K, Matsuo K, Matsuda T and Kuwano M (1992) DNA topoisomerase-targeting antitumor agents and drug resistance. Anti-Cancer Drugs 3: 323-330
37. Van der Zee AGJ, Hollema HH, De Bruijn HWA, Willemse PHB, Boonstra H, Mulder NH, Aalders JG, and De Vries EGE (1995) Cell biological markers of drug resistance in ovarian carcinoma. Gynecol Oncol 58: 165-178
38. Van Ommen GJB, Breuning MH and Raap AK (1995) FISH in genome research and molecular diagnostics. Curr Opin Genet Devel 5: 304-308
39. Versantvoort CHM, Withoff S, Broxterman HJ, Kuiper CM, Scheper KJ, Mulder NH and De Vries EGE (1995) Resistance-associated factors in human small-cell lung-carcinoma GLC4 sub-lines with increasing adriamycin resistance. Int J Cancer 61: 375-380